Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Institut Regional Du Cancer De Montpellier

Oribase Pharma

Institut Regional Du Cancer De Montpellier-val D'aurelle

Centre National De La Recherche Scientifique

Gamamabs Pharma Sa

Centre Val D'aurelle—paul Lamarque

Inserm (institut National De La Sante Et De La Recherche Medicale)

Gamamabs Pharma

Inserm

Université De Montpellier I

Université De Montpellier 1

Thierry Chardes

Christel Larbouret

Andre Pelegrin

Bruno Robert

Bénédicte Fauvel

Nadège Gaborit

Christian Larroque

Aziz Yasri

Yassamine Lazrek

Wilhem Leconet

Gwenael Cheve

Martine Cerutti

Jean-Marc Barret

Pierre Martineau

André Pelegrin

Philippe Mondon

Bernard Pau

Claude Granier

Abdelhakim Kharrat

Khalil Bouayadi

Gwénaël Cheve

Olivier Dubreuil

Christian Devaux

Emmanuelle Liaudet-Coopman

Yahya Ashraf

Nadege A Gaborit

Cédric Bes

Laurence Briant-Longuet

Gérard Devauchelle

Nadège A Gaborit

Jean-Francois Prost

Stephane Degove

The invention relates to human anti-Cath-D neutralizing monoclonal antibodies and uses thereof. More particularly, the invention relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.

Human monoclonal antibodies fragments inhibiting both the Cath-D catalytic activity and its binding to the LRP1 receptor

The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.

Neuregulin allosteric anti-HER3 antibody

The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.

Anti-Axl antibodies and uses thereof

The invention relates to antibodies against HER3 and their use in the treatment of cancer.

Antibodies against HER3

The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.

The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.

Anti-human HER3 antibodies and uses thereof

A mutant Fab fragment of the 13B8.2 anti-CD4 antibody that binds a CD4 molecule and includes a mutation of at least one residue in a position situated in the VH variable domain of the heavy chain and/or in a position situated in the V&#x3ba; variable domain of the light chain.

Mutant Fab fragments of the chimeric 13B8.2 anti-CD4 antibody and their applications

Growing community of inventors

Montpellier, France

Thierry Chardes